Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report.
BACKGROUND
Endometrial hyperplasia in patients with a history of breast cancer presents a therapeutic dilemma. The standard conservative therapy for hyperplasia, high-dose progestins, is contraindicated in breast cancer. Anastrozole, an aromatase inhibitor, is becoming first-line adjuvant therapy for breast cancer in postmenopausal women and may have protective effects on the endometrium.


METHODS
A 51-year-old, obese woman with a history of breast cancer presented with a 2-day history of heavy postmenopausal bleeding. Endometrial biopsy demonstrated simple hyperplasia without cellular atypia. After consultation with the patient's oncologist, the patient received adjuvant anastrozole therapy for the breast cancer; it led to resolution of the endometrial hyperplasia.


CONCLUSIONS
Adjuvant therapy with anastrozole may be beneficial in resolving endometrial hyperplasia in patients with breast cancer.
Stilwill
Sarah E
SE
Department of Obstetrics and Gynecology, University of Vermont College of Medicine, Burlington, USA.
Cooper
Brian C
BC
D000077384:Anastrozole; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D004714:Endometrial Hyperplasia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D017698:Postmenopause; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D014592:Uterine Hemorrhage / Q000209:etiology
D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole